ReviewMedical science monitor : international medical journal of experimental and clinical research2025
Signaling Pathways and Therapeutic Approaches in Post-Myocardial Infarction Fibrosis.
Review in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Butyrate and Butyrate-Producing Bacteria in Cardiovascular-Kidney-Metabolic Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
- The role of the bidirectional regulatory network between immune cells and stromal cells in cardiac repair and fibrosis following myocardial infarction.Frontiers in immunology · 2026Review
- The quality and reliability of short videos about myocardial infarction on TikTok: a cross-sectional study.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI) is a leading cause of myocardial fibrosis, contributing significantly to heart disease morbidity and mortality. Recent advancements have elucidated various signaling pathways and therapeutic strategies targeting myocardial fibrosis following MI. This review summarizes key pathways, including TGF-ß1, PI3K/AKT, STAT3, AMPK, Nrf2, NF-kappaB, NLRP3 inflammasome, Wnt/b-catenin, MAPK, and P53, highlighting their potential in therapeutic interventions in recent years. Drug therapy, protein therapy, gene therapy, physical therapy, cell therapy, and exercise training have all shown promise in mitigating fibrosis through these pathways. Notably, multi-pathway therapeutic strategies offer a comprehensive approach to managing myocardial fibrosis, with the TGF-ß1 pathway acting as a central hub in the regulatory network. This review underscores the need for further clinical studies to optimize therapeutic strategies and improve outcomes for patients with myocardial fibrosis following MI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.